




**Most CDMOs are built for clinical batches.
We are built for licensed supply.**

With integrated development in Taiwan and commercial-scale drug substance manufacturing in the United States, we deliver a unified lifecycle pathway from first-in-human to global market supply — deliberately structured to reduce tech transfer risk and support launch durability.

U.S.-ANCHORED COMMERCIAL BIOLOGICS PLATFORM

Development Center of Excellence Zhubei, Taiwan

- ✦ DNA to DP in 10 months
- ✦ Cell line, process & analytical development
- ✦ IND-enabling support
- ✦ FIH clinical drug substance manufacturing
- ✦ Designed for structured tech transfer to U.S. commercial facilities

Biosecure-Ready U.S. Commercial Manufacturing San Diego, CA | Rockville, MD

- ✦ FDA-registered facilities
- ✦ 20,000L installed U.S. single-use capacity (expandable to 30,000L)
- ✦ 7 × 2,000L single-use bioreactors (flexible configuration up to 3 × 5,000L and 4 × 2,000L)
- ✦ 100% single-use architecture
- ✦ Closed processing systems minimizing cross-contamination risk
- ✦ Designed to support evolving U.S. supply chain resilience expectations

PROVEN WHERE IT MATTERS

4

active commercial programs supplying 6 global markets

100%

first-pass PPQ success

>200

GMP batches executed

>60

commercial batches

16

GMP tech transfers executed

48+

biologics & biosimilars developed

\$150M

invested in U.S. commercial expansion* (2025–2026)

2

FDA-registered U.S. facilities

DESIGNED TO REDUCE LIFECYCLE RISK

Switching CDMOs between clinical and commercial phases introduces delay, tech transfer risk, regulatory exposure, and capital inefficiency.

Bora Biologics eliminates that transition risk. Our global tech transfer pathway is structured to move programs from development in Taiwan to late-stage and licensed production in the United States under one integrated quality system.

Commercial Discipline at Every Phase

- ✦ Mature QMS refined through multiple regulatory inspections
- ✦ In-house analytical, release, and stability capabilities
- ✦ End-to-end CMC and regulatory support from IND to BLA
- ✦ Integrated program governance with defined escalation pathways

Bi-Coastal U.S. Anchoring

- ✦ U.S.-anchored commercial manufacturing
- ✦ Diversified Asia-U.S. operations
- ✦ Long-term infrastructure investment
- ✦ Scalable capacity aligned with global demand

PARTNER WITH A PLATFORM BUILT FOR COMMERCIAL

If your goal is licensed product in global markets, Bora Biologics is engineered to deliver it.



www.borabiologics.com

BD@borabiologics.com

+1 (858) 210-4100

*Includes \$26.5 million directly invested by Bora Biologics; remaining investment made by Bora Pharmaceuticals (2025–2026).



10394 Pacific Center Ct, San Diego, CA 92121 USA
9704 Medical Center Drive Rockville, MD 20850 USA
3F, No 22, Sec 2, Shengyi Rd, Zhubei City, Hsinchu County 302, Taiwan

©2026 Bora Biologics. All rights reserved.